A key advantage of the patent-pending AB-101 Platform Biomaterial is it is composed of multiple bioactive compounds, the result of AB-101 plant-derived sourcing. AB-101’s multiple bioactives are the reason Alphyn’s designates AB-101 as a new class of drugs it calls Multi-Target Therapeutics™.
Multi-Target Therapeutics™, as a result of AB-101’s multiple bioactive compounds, has important advantages:
- Each AB-101 product has multiple compounds, and therefore multiple ways or mechanisms, to attack each disease – to be more effective
- A rich new product pipeline with multiple AB-101 based products for multiple diseases
- A faster, lower cost path to FDA marketing authorization